Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Cellular Signalling
- Vol. 81, 109931
Abstract
No abstract availableKeywords
Funding Information
- China Scholarship Council
- U.S. Department of War
This publication has 48 references indexed in Scilit:
- IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder CancerPLOS ONE, 2013
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell deathBritish Journal of Haematology, 2009
- β1 Integrin Adhesion Enhances IL-6–Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and ProliferationCancer Research, 2009
- Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylationProceedings of the National Academy of Sciences, 2008
- IL-6 involvement in epithelial cancersJournal of Clinical Investigation, 2007
- Structural model of full‐length human Ku70–Ku80 heterodimer and its recognition of DNA and DNA‐PKcsEMBO Reports, 2006
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- SHP2 Mediates the Protective Effect of Interleukin-6 against Dexamethasone-induced Apoptosis in Multiple Myeloma CellsJournal of Biological Chemistry, 2000
- Emerging roles of caspase-3 in apoptosisCell Death & Differentiation, 1999